The Role of data in Phar­maceu­ti­cal Indus­try and clini­cal trials

Back­ground

Not all pati­ents who are diagno­sed with Auto­an­ti­bo­dies in Breast Cancer Detec­tion (ABCD) may respond to treat­ment and drugs avail­able today. Their last alter­na­tive is to explore drugs and treat­ment in clini­cal trials. Unfor­tu­n­a­tely, avai­la­bi­lity of such infor­ma­tion in a cohe­rent simple to under­stand plat­form is a luxury. Clini­cal trials are done when all avail­able treat­ments have proven unsuc­cess­ful yet the process of enrol­ling in a clini­cal trial can be expen­sive, time consuming and compli­ca­ted for the pati­ents. High cost of rese­arch and deve­lo­p­ment in drug design results in higher drug prices and higher insurance premi­ums. The US government esti­ma­tes that as at May 2018, only 3% of cancer pati­ents are enrol­led for clini­cal trials. How can clini­cal trials be made less expen­sive, effi­ci­ent and more acces­si­ble to pati­ents?

Data­sets used

One of the reasons why clini­cal trials fail is due to data collec­tion process. A first step is access to cura­ted data­base of clini­cal trials where pati­ents can directly search based on cate­go­ries and loca­tion. In addi­tion, anony­mi­sed pati­ent infor­ma­tion and drug analy­sis report can be viewed on the data market­place. Avai­la­bi­lity of this infor­ma­tion rather than oral recom­men­da­tion from health person­nel will incre­ase the percen­tage of pati­ents invol­ved in such clini­cal trials. The process even beco­mes more effi­ci­ent when the Rese­arch team have digi­tal copies (not pdf or fax) of pati­ent medi­cal records and previous treat­ment reports. The Adva­neo data market­place has been deve­lo­ped to address this.

Adva­neo Data Market­place

Among the nume­rous features of the data market­place of rele­vance to the health­care sector espe­cially clini­cal trials is ensu­ring secu­rity and privacy while faci­li­ta­ting seam­less exchange of data to selec­ted medi­cal insti­tu­ti­ons. The Adva­neo data market­place offers:



Secu­rity and Privacy: No data­set will be stored on the market­place rather, veri­fied data endpoints to where such infor­ma­tion can be obtai­ned is provi­ded in addi­tion to a stan­dar­di­sed descrip­tion of the data­set (meta­data). The data provi­der (patient/hospital) main­tains the data­set with 100% data gover­nance.



Broker Service: Supple­men­tary infor­ma­tion such as dietary habits, acti­vity and sleep cycle can be inde­pendently gathe­red by the pati­ent using a variety of smart­phone apps and weara­bles. This data which belongs to the pati­ent can be shared freely or traded by the pati­ent. Our broker service ensu­res this is done with no compli­ca­ted over­head on the data provi­der. Such data­sets will prevent depen­dence on subjec­tive response during clini­cal trials.



Closed User Groups: The progress and final results of clini­cal trials can become trade secrets that should kept private to parties invol­ved in the process. The data market­place provi­des the option to create closed user groups. The exis­tence of such groups and members will remain inco­gnito. More import­antly the meta­data is only visi­ble by the members of the group and the data­set are exchange directly between pairs.

Impact

The search for appro­priate drugs to treat cancer by using clini­cal trial analy­sis is curr­ently a long expen­sive process. Colla­tion and avai­la­bi­lity of high quality data­sets will be a signi­fi­cant step towards trans­forming the process. In addi­tion, the possi­bi­li­ties become endless when machine lear­ning tools are applied to these data­sets for pati­ent to clini­cal trial matching, early anomaly diagno­sis and data driven drug design process. The avai­la­bi­lity of data will also aid machine lear­ning appli­ca­ti­ons in preven­tion and early diagno­sis of health pande­mics. In fact, deep lear­ning appli­ca­ti­ons will contri­bute 3 billion dollars to the health­care sector by 2025. This will lead to signi­fi­cant reduc­tion in cost of health­care while crea­ting new busi­ness oppor­tu­nities in the health­care sector.

Phone.: 0211 8766910
Email: hello@advaneo.de
Your Contact: Jürgen Bret­feld

Use of cookies
In order to optimize the website and to improve it continuously, ADVANEO uses cookies. By continuing to use the website, you agree to the use of cookies. Further information can be found in our privacy policy declaration.
-Click here to unsubscribe.